Watson debuts generic Nexium in Europe; Mylan launches Amidate copy in USA
US generics firm Watson Pharmaceuticals (NYSE: WPI) said yesterday that its third-party business Specifar has launched esomeprazole tablets to its customers in Europe. Watson’s Arrow Generiques in France has begun distribution to its customers under the Arrow label.
The product, a generic version of Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) proton pump inhibitor Nexium, has already been launched to Specifar customers in France, Iceland, Spain and Switzerland and will be launched to customers in other European markets this year.
In 2011, esomeprazole had sales of roughly 793 million euros ($963 million) in the European Union, according to IMS Health data quoted by Watson. The generic product was developed by at the company’s Specifar subsidiary, located in Athens, Greece, and manufactured in Spain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze